Page One | Page Two | Page Three | Page Four | Page Five

       S p e e d i n g the

Now there is a complete, automated DNA analysis package for the individual researcher. The tedious task of sequencing DNA is fully automated on the CEQ TM 2000 DNA Analysis System. The CEQ 2000 utility was expanded in 1999 with the introduction of a fragment analysis capability, allowing researchers to isolate genes that play a role in disease processes.

Pharmaceutical company research spending has nearly doubled every five years since 1970. Companies now put back into R&D $1 out of every $5 of pharmaceutical revenues.

Pharmaceutical Research and Manufacturers of America

“ There is a growing global demand for new drugs and enhanced therapeutics, in part because of an aging population that is anxious to prolong and improve the quality of life. Yet, developing just one new drug can take up to a decade or more and cost upwards of half a billion dollars. Since drug candidates are usually patented while in development, pharmaceutical companies must move quickly to introduce a marketable product which maximizes the commercial payback of the patent protection. Our focus is to help these companies accelerate the drug discovery process and control costs. With offerings like the SAGIANTM Core System for high-throughput screening, Beckman Coulter brings increased speed to the process by which new drug targets can be identified and compounds screened. We also continue to enhance the quality of information generated with tools like the SAGIANTM Automated Assay Optimization software introduced this year. This software helps laboratory scientists develop more robust screening assays on the Biomek® 2000 Laboratory Automation Workstation, the backbone of our SAGIAN Core System.”

Jack Finney Vice President Bioresearch Division